Current and upcoming treatment strategies after CDK4/6 inhibitors for patients with ER+/HER2- advanced breast cancer

The publication of this article was funded by Menarini Stemline.

Summary

This video showcases a key symposium from the 2023 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain. The presentation focused on advancing the treatment of oestrogen-receptor positive (ER+) human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer. The symposium aimed to address the pressing issue of resistance to cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in these patients, particularly in the second-line (2L) setting. Expert clinicians discussed the challenges of resistance, emphasising the need for improved 2L treatment options, especially for patients with oestrogen receptor alpha gene (ESR1) mutations.

A major highlight of the symposium was the discussion of the recently-approved oral selective oestrogen receptor down-regulator, elacestrant, for 2L monotherapy. Importantly, the symposium underscored the significance of ESR1 mutation testing at each stage of metastatic treatment, as it has become a predictive factor for the efficacy of elacestrant. This video provides valuable insights into the evolving landscape of breast cancer treatment, and the potential solutions for patients facing this challenging disease.